​

Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NRIX Stock Forecast

Nurix Therapeutics (NRIX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $22.67, with a high of $35.00 and a low of $16.00. This represents a 98.16% increase from the last price of $11.44.

$10 $15 $20 $25 $30 $35 High: $35 Avg: $22.67 Low: $16 Last Closed Price: $11.44

NRIX Stock Rating

Nurix Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

NRIX Price Target Upside V Benchmarks

TypeNameUpside
StockNurix Therapeutics98.16%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts-214
Avg Price Target-$16.50$29.64
Last Closing Price$11.44$11.44$11.44
Upside/Downside-44.23%159.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256102--18
Mar, 257101--18
Feb, 25791--17
Jan, 25791--17
Dec, 24791--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2025Leerink Partners$16.00$13.9314.86%39.86%
Feb 03, 2025Terence FlynnMorgan Stanley$17.00$18.95-10.29%48.60%
Dec 05, 2024Etzer DaroutBMO Capital$35.00$20.0674.48%205.94%
Oct 24, 2024David DaiUBS$35.00$24.7841.24%205.94%
Oct 21, 2024Robert BurnsH.C. Wainwright$30.00$25.1919.09%162.24%
Oct 15, 2024Matthew BieglerOppenheimer$35.00$24.8740.73%205.94%
Oct 15, 2024Derek ArchilaWells Fargo$32.00$25.1627.19%179.72%
Oct 14, 2024Stephen WilleyStifel Nicolaus$34.00$24.9836.11%197.20%
Oct 11, 2024Roger SongJefferies$41.00$23.0477.95%258.39%
Sep 05, 2024Brian SkorneyRobert W. Baird$26.00$24.446.38%127.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2025RBC CapitalOutperformOutperformhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 21, 2024H.C. WainwrightBuyBuyhold
Oct 15, 2024OppenheimerOutperformOutperformhold
Oct 15, 2024Wells FargoOverweightOverweighthold
Oct 14, 2024RBC CapitalOutperformOutperformhold
Oct 14, 2024Piper SandlerOverweightOverweighthold
Oct 11, 2024JefferiesBuyinitialise
Sep 04, 2024RBC CapitalBuyBuyhold
Sep 04, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-2.76$-2.73$-3.42$-2.65$-2.88-----
Avg Forecast$-2.01$-2.54$0.59$-2.34$-2.81$-3.14$-3.37$-3.44$-2.45$-0.03
High Forecast$-1.43$-1.81$1.55$-1.49$-2.61$-2.21$-1.82$-1.77$-1.51$-0.02
Low Forecast$-2.68$-3.40$-0.38$-2.94$-3.04$-3.78$-4.53$-4.71$-4.76$-0.07
Surprise %37.31%7.48%-679.66%13.25%2.49%-----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$17.82M$29.75M$38.63M$76.99M$54.55M-----
Avg Forecast$14.04M$35.21M$47.31M$94.04M$54.58M$57.44M$71.12M$100.48M$245.89M$536.49M
High Forecast$17.66M$44.28M$56.78M$140.13M$64.72M$68.99M$147.28M$104.54M$424.06M$925.25M
Low Forecast$10.94M$27.43M$37.85M$68.35M$41.35M$47.20M$44.47M$96.42M$172.97M$377.40M
Surprise %26.89%-15.50%-18.36%-18.14%-0.05%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Nov 20 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 20Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-43.24M$-117.19M$-166.04M$-143.95M$-193.57M-----
Avg Forecast$-109.22M$-98.03M$-226.20M$-143.95M$-193.57M$-200.83M$-291.81M$-314.78M$-164.44M$-2.30M
High Forecast$-77.86M$-78.43M$-180.96M$-115.16M$-175.17M$-148.02M$-121.87M$-118.75M$-101.05M$-1.41M
Low Forecast$-145.82M$-117.64M$-271.43M$-172.74M$-204.03M$-253.65M$-303.86M$-316.43M$-319.36M$-4.47M
Surprise %-60.41%19.55%-26.59%-------

NRIX Forecast FAQ

Is Nurix Therapeutics stock a buy?

Nurix Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nurix Therapeutics is a favorable investment for most analysts.

What is Nurix Therapeutics's price target?

Nurix Therapeutics's price target, set by 13 Wall Street analysts, averages $22.67 over the next 12 months. The price target range spans from $16 at the low end to $35 at the high end, suggesting a potential 98.16% change from the previous closing price of $11.44.

How does Nurix Therapeutics stock forecast compare to its benchmarks?

Nurix Therapeutics's stock forecast shows a 98.16% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Nurix Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 38.89% Strong Buy, 55.56% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 41.18% Strong Buy, 52.94% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is Nurix Therapeutics’s EPS forecast?

Nurix Therapeutics's average annual EPS forecast for its fiscal year ending in November 2025 is $-3.14, marking a 9.03% increase from the reported $-2.88 in 2024. Estimates for the following years are $-3.37 in 2026, $-3.44 in 2027, $-2.45 in 2028, and $-0.03 in 2029.

What is Nurix Therapeutics’s revenue forecast?

Nurix Therapeutics's average annual revenue forecast for its fiscal year ending in November 2025 is $57.44M, reflecting a 5.29% increase from the reported $54.55M in 2024. The forecast for 2026 is $71.12M, followed by $100.48M for 2027, $245.89M for 2028, and $536.49M for 2029.

What is Nurix Therapeutics’s net income forecast?

Nurix Therapeutics's net income forecast for the fiscal year ending in November 2025 stands at $-201M, representing an 3.75% increase from the reported $-194M in 2024. Projections indicate $-292M in 2026, $-315M in 2027, $-164M in 2028, and $-2.301M in 2029.